Literature DB >> 4531352

Immunotherapy for acute myelogenous leukaemia.

R Powles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4531352      PMCID： PMC2149078     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN： 0306-9443


× No keyword cloud information.
  5 in total

1.  Management of adult acute myelogenous leukaemia.

Authors:  D Crowther; R L Powles; C J Bateman; M E Beard; C L Gauci; P F Wrigley; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1973-01-20

2.  Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults.

Authors:  J P Whitecar; G P Bodey; E J Freireich; K B McCredie; J S Hart
Journal:  Cancer Chemother Rep       Date:  1972-08

3.  Approaches to the immunological treatment of cancer in man.

Authors:  G Mathé
Journal:  Br Med J       Date:  1969-10-04

4.  Recognition of leukaemia cells as foreign before and after autoimmunization.

Authors:  R L Powles; L A Balchin; G H Fairley; P Alexander
Journal:  Br Med J       Date:  1971-02-27

5.  Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer.

Authors:  G A Currie
Journal:  Br J Cancer       Date:  1972-06       Impact factor: 7.640
  5 in total
  8 in total

1.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

2.  Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice.

Authors:  N A Sher; S D Chaparas; L E Greenberg; S Bernard
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

3.  Colony-forming ability of marrow from patients receiving immunotherapy during chemotherapy-induced remission in acute myeloid leukaemia.

Authors:  M Y Gordon; R L Powles; I D Douglas
Journal:  J Clin Pathol       Date:  1977-01       Impact factor: 3.411

4.  Inability to demonstrate lytic antibodies to autologous leukaemia cells in the sera from remission patients with acute myelogenous leukaemia treated with active specific immunotherapy.

Authors:  B J Chapuis; R Powles; P Alexander
Journal:  Clin Exp Immunol       Date:  1978-05       Impact factor: 4.330

5.  Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.

Authors:  R Harris; S R Zuhrie; C B Freeman; G M Taylor; J E MacIver; C G Geary; I W Delamore; P J Hull; J A Tooth
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

6.  Immunotherapy for acute myelogenous leukaemia.

Authors:  R L Powles; D Crowther; C J Bateman; M E Beard; T J McElwain; J Russell; T A Lister; J M Whitehouse; P F Wrigley; M Pike; P Alexander; G H Fairley
Journal:  Br J Cancer       Date:  1973-11       Impact factor: 7.640

7.  Adult acute leukaemia.

Authors:  K Atkinson; D G Wells; H M Clink; H E Kay; R Powles; T J McElwain
Journal:  Br J Cancer       Date:  1974-09       Impact factor: 7.640

8.  Failure to detect autologous antibodies in the remission sera of patients with AML: complications introduced by the presence of rheumatoid factor.

Authors:  S E James; C J Dean; P Alexander
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.